Why the study?
The study was conducted to compare fetal and neonatal cardiac morphology between fetuses and infants of mothers with gestational diabetes mellitus and normal controls.
Does well-controlled gestational diabetes mellitus affect fetal and neonatal cardiac morphology compared to normal controls?
Does well-controlled gestational diabetes mellitus affect fetal and neonatal cardiac morphology compared to normal controls?
Good control of maternal blood glucose in gestational diabetes mellitus appears to prevent fetal and neonatal cardiac morphological abnormalities, resulting in cardiac dimensions comparable to normal controls.
GDM-associated cardiac changes may prompt closer fetal monitoring; leaves open long-term risks and need for prospective trials.
OBJECTIVE: To compare fetal and neonatal cardiac morphology in fetuses of mothers with gestational diabetes mellitus (GDM) with the controls. PATIENTS AND METHODS: Pregnant women at average risk of GDM underwent 100-g, 3-h-OGTT at 24-28 weeks of gestation for diagnosis of GDM. Both GDM group and the control group underwent fetal echocardiography at 32-36 weeks to assess cardiac dimensions. The neonates underwent echocardiography within 48 h after birth to assess cardiac morphology. RESULTS: A total of 154 pregnant women were recruited, including 60 in the GDM group and 94 in the control group. All of the study group were well controlled for GDM. Most baseline characteristics of both groups were comparable. All obstetric outcomes were not significantly different between the two groups. Morphological cardiac dimensions in the fetuses and newborns of both groups were also not significant different. Subgroup analysis in the study group showed no significantly different in cardiac morphology between the group with diet control and that of insulin control. CONCLUSION: Fetal and neonatal cardiac morphologic changes among mothers with well-controlled GDM are not significantly different from those in the controls. It is possible that good control of maternal blood glucose can prevent fetal and neonatal cardiac abnormalities.
No takes yet. Share an insight, caveat, or question.
Santanapipatkul et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: